Intelligent Bio Solutions Inc. (NASDAQ: INBS) completed its initial clinical Cut-off Study for FDA 510(k) submission of its fingerprint-based drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE